QIAGEN N.V. (QGEN) is a global leader in molecular diagnostics (MDx) and life sciences operating in over 35 locations worldwide. It has its global headquarters in Venlo, the Netherlands, and its operations center in Hilden, Germany. The U.S. development and manufacturing facility is located in Germantown, Maryland.
QIAGEN is listed on both the Frankfurt Stock Exchange and NASDAQ, demonstrating its worldwide influence in the bio-tech industry. The company provides Sample to Insight solutions that are used by academia, pharmaceutical research, and molecular diagnostics labs to gain valuable molecular insights from samples containing the building blocks of life (DNA, RNA, and proteins).
Since its establishment in 1984, the company has focused on providing innovative technologies and products for pre-analytical sample preparation and associated molecular assay technologies. QIAGEN's product portfolio enlists more than 500 core consumable products as well as automated solutions for sample preparation.
The company's revolutionary molecular diagnostic tests are used in clinical settings for infectious diseases such as HIV, tuberculosis, HPV, hepatitis B and C. Furthermore, QIAGEN contributes to personalized health care by providing oncology companion diagnostics to select appropriate therapies for advanced cancers. Not only does it help in the prediction of disease risk but also in the prevention, early detection, and treatment monitoring of diseases.
Their leading product, QIAstat-Dx system for syndromic testing, handles various PCR (Polymerase Chain Reaction) based tests in single, easy-to-use cartridges. This allows for fast and comprehensive analysis of complex clinical syndromes, thus making it an essential tool in emergency and critical care.
QIAGEN is committed to precision medicine, aspiring to make improvements in life possible by enabling its customers to achieve breakthroughs in healthcare. This is done through a robust focus on innovation, a broad product portfolio, and a promising pipeline.
Its commitment to ethical, social, and environmental responsibility stands out; the well-being of customers, employees, and communities, and the protection of the environment, are core elements of the company's mission and vision.
Poised at the intersection of biology and digitalization, QIAGEN is building bridges between these two worlds to continue to realize the full potential of Precision Medicine and revolutionize the future of healthcare.
The remarkable progress in biological understanding, enabled by QIAGEN's high-quality products, has proven beneficial in critical areas of human health and has made QIAGEN a trusted partner in global efforts to combat diseases.